WCLC 2025 - Posters & ePosters-P3.18.75 Tislelizumab in Combination With EP/EC Chemotherapy and Sequent Anlotinib Followed by Radiotherapy as First-Line Treatment for ES-SCLC

P3.18.75 Tislelizumab in Combination With EP/EC Chemotherapy and Sequent Anlotinib Followed by Radiotherapy as First-Line Treatment for ES-SCLC

Asset Subtitle

ZhenTian Liu

Meta Tag

Speaker ZhenTian Liu

Topic Clinical Trials in Progress